Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-311: Zanzalintinib vs Everolimus in Advanced Neuroendocrine Tumors
NCT06943755Phase 3Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2025
- Primary completion
- Jun 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of zanzalintinib in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Progression-Free Survival at 48 months. Started Jul 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06943755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943755.